Effect of leukocyte antibodies on the fate in vivo of indium-111-labeled granulocytes.
The effect of different leukocyte antibodies on the fate in vivo of granulocytes is not known. Thus, the optimum in vitro serologic tests to determine a safe and effective granulocyte transfusion or to diagnose immune destruction of granulocytes in other clinical situations have not been identified. We have studied the effect of granulocyte agglutinating (GA), granulocytotoxic (GC), and lymphocytotoxic (LC) antibodies on the intravascular recovery and half-life (t 1/2) and the extravascular localization of Indium-111-granulocytes in 50 patients. GA antibodies caused reduced granulocyte recovery and t 1/2 in three of three non-neutropenic patients (one with anti-NB1), increased sequestration of cells in the liver, and failure of granulocytes to localize at sites of infection in two of two patients (one with anti-NA1). In contrast, GC antibodies in five patients and LC antibodies in one patient did not cause reduced intravascular recovery or t 1/2 of granulocytes. In nine patients with GC and six patients with LC antibodies, incompatible granulocytes localized at known sites of infection. It appears that GA, but not GC nor LC, antibodies alter the fate in vivo of granulocytes.
D000372:Agglutination Tests; D000906:Antibodies / Q000276:immunology*; D003601:Cytotoxicity Tests, Immunologic; D006098:Granulocytes / Q000276:immunology*; D006801:Humans; D007204:Indium; D007962:Leukocytes / Q000276:immunology*; D008099:Liver / Q000000981:diagnostic imaging; D008214:Lymphocytes / Q000276:immunology; D011868:Radioisotopes; D011877:Radionuclide Imaging; D013154:Spleen / Q000000981:diagnostic imaging
D000906:Antibodies; D011868:Radioisotopes; D007204:Indium